Neurocrine Biosciences, Inc.
NBIX
$131.14
-$1.24-0.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.23% | 10.91% | 2.68% | -17.28% | 36.68% |
| Total Depreciation and Amortization | 11.07% | 15.56% | 15.38% | 26.67% | 27.23% |
| Total Amortization of Deferred Charges | -- | -- | -200.00% | -200.00% | -- |
| Total Other Non-Cash Items | 63.61% | 43.45% | 90.63% | 167.75% | 171.44% |
| Change in Net Operating Assets | -570.83% | 8.07% | 128.58% | -120.89% | -168.09% |
| Cash from Operations | 31.46% | 33.67% | 6.96% | -17.90% | 52.71% |
| Capital Expenditure | 10.99% | -20.39% | -7.82% | -21.61% | -34.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -160.05% | -5.40% | 94.29% | 95.57% | 79.81% |
| Cash from Investing | -108.52% | -7.49% | 84.72% | 88.00% | 72.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 100.00% | -- | -- |
| Issuance of Common Stock | 5.98% | -30.78% | -40.74% | -33.62% | 86.98% |
| Repurchase of Common Stock | 44.10% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 92.13% | -126.66% | -127.83% | -631.10% | -845.33% |
| Foreign Exchange rate Adjustments | -- | -150.00% | -33.33% | -100.00% | -100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,751.93% | -116.06% | 706.34% | -169.08% | -56.03% |